Cytokines in the Respiratory Airway as Biomarkers of Severity and Prognosis for Respiratory Syncytial Virus Infection: An Update.

Simple item page
dc.article.number1154
dc.catalogadorpva
dc.contributor.authorYaneisi Vázquez
dc.contributor.authorLiliana González
dc.contributor.authorLoreani Noguera
dc.contributor.authorPablo A. González
dc.contributor.authorClaudia A. Riedel
dc.contributor.authorPablo Bertrand
dc.contributor.authorSusan M. Bueno
dc.date.accessioned2024-03-04T15:19:38Z
dc.date.available2024-03-04T15:19:38Z
dc.date.issued2019
dc.description.abstractThe human respiratory syncytial virus (hRSV) is one of the most important causes of upper and lower respiratory tract infections in children and the main cause of bronchiolitis worldwide. Disease manifestations caused by hRSV may vary from mild to severe, occasionally requiring admission and hospitalization in intensive care units. Despite the high morbidity rates associated to bronchiolitis, treatment options against hRSV are limited and there are no current vaccination strategies to prevent infection. Importantly, the early identification of high-risk patients can help improve disease management and prevent complications associated with hRSV infection. Recently, the characterization of pro- and anti-inflammatory cytokine patterns produced during hRSV-related inflammatory processes has allowed the identification of potential prognosis biomarkers. A suitable biomarker should allow predicting the severity of the infection in a simple and opportune manner and should ideally be obtained from non-invasive samples. Among the cytokines associated with hRSV disease severity, IL-8, interferon-alpha (IFN-alpha), and IL-6, as well as the Th2-type cytokines thymic stromal lymphopoietin (TSLP), IL-3, and IL-33 have been highlighted as molecules with prognostic value in hRSV infections. In this review, we discuss current studies that describe molecules produced by patients during hRSV infection and their potential as biomarkers to anticipate the severity of the disease caused by this virus.
dc.fechaingreso.objetodigital2024-05-22
dc.format.extent13 páginas
dc.fuente.origenORCID
dc.identifier.doi10.3389/fimmu.2019.01154
dc.identifier.eissn1664-3224
dc.identifier.urihttps://doi.org/10.3389/fimmu.2019.01154
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/82438
dc.information.autorucFacultad de Ciencias Biológicas; Bueno Ramirez, Susan Marcela; 0000-0002-7551-8088; 113541
dc.issue.numero2019
dc.language.isoen
dc.nota.accesoContenido completo
dc.pagina.final13
dc.pagina.inicio1
dc.revistaFrontiers in Immunology
dc.rightsacceso abierto
dc.rights.licenseCC BY 4.0 DEED Attribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectBiomarker
dc.subjectCytokines
dc.subjectLRTI
dc.subjecthRSV
dc.subjectSeverity
dc.subjectPrognosis
dc.subject.ddc570
dc.subject.deweyBiologíaes_ES
dc.titleCytokines in the Respiratory Airway as Biomarkers of Severity and Prognosis for Respiratory Syncytial Virus Infection: An Update.
dc.typeartículo de revisión
dc.volumen10
sipa.codpersvinculados113541
sipa.trazabilidadORCID;2024-01-15
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
fimmu-10-01154.pdf
Size:
808.53 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas